Regenxbio (RGNX) Cash from Financing Activities (2014 - 2025)

Regenxbio's Cash from Financing Activities history runs 12 years deep, the most recent figure standing at -$9.6 million for Q4 2025.

• In Q4 2025, Cash from Financing Activities fell 23.82% year-over-year to -$9.6 million; the TTM figure through Dec 2025 stood at $116.8 million (up 25.99% YoY), while the FY2025 annual figure was $116.8 million, up 25.99% from the prior year.
• Cash from Financing Activities was -$9.6 million for Q4 2025 at Regenxbio, down from -$7.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $211.3 million in Q1 2021 to a low of -$12.0 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged $17.0 million across 5 years, with a median of -$7.3 million in 2021.
• Biggest YoY gain for Cash from Financing Activities was 7552.52% in 2021; the steepest drop was 436.27% in 2021.
• A 5-year view of Cash from Financing Activities shows it stood at -$7.6 million in 2021, then declined by 17.12% to -$8.9 million in 2022, then slumped by 34.1% to -$12.0 million in 2023, then surged by 35.3% to -$7.7 million in 2024, then dropped by 23.82% to -$9.6 million in 2025.
• The last three Cash from Financing Activities figures came in at -$9.6 million (Q4 2025), -$7.1 million (Q3 2025), and $139.2 million (Q2 2025), per Business Quant data.